Radical prostatectomy in localised cancer of the prostate;Radikal prostatektomi for lokaliseret cancer prostatae

Ugeskrift for Laeger

Volumn 160, Issue 31, 1998, Pages 4505-4509

  Brasso, Klaus ^a   Iversen, Peter ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; DENMARK; HUMAN; MALE; METHODOLOGY; MORTALITY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; QUALITY OF LIFE; REVIEW;

DENMARK; HUMANS; MALE; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 0032572432     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Gil-Vernet JM. Prostate cancer: anatomical and surgical considerations. Br J Urol 1996; 78: 161-8.
2. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992; (suppl 4): 129-38.
3. Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, Lieber MM. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor de-oxyribonucleic acid ploidy. J Urol 1989; 142: 1262-5.
4. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 1104.
5. Soloway MS, Sharrifi R, Wajsman Z, Mcleod D, Wood DP Jr. Pura-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer J Urol 1995; 154: 424-8
6. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or B0) prostate cancer. Urol Clin North Am 1993; 20: 687-93.
7. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 1993; 149: 516-8.
8. Schröder FH, van den Ouden D, Davidson P The limits of surgery in the cure of prostatic carcinoma. Eur Urol Update Ser 1992; 1: 18-23.
9. Norberg M, Holmberg L, Busch C, Häggman M, Egevad L, Magnusson A. Multiple transrectal ultrasound-guided biopsies for the detection of prostate cancer and determination of tumor volume, grade, and seminal vesicle invasion. Eur Radiol 1996; 6: 56-61.
10. Kabalin JN, McNeal JE, Johnstone IM, Stamey TA. Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology 1995; 46: 65-70.
11. Kleer E, Oesterling JE. PSA and staging of localized prostate cancer. Urol Clin North Am 1993; 20: 695-704.
12. Thickman D, Speers WC, Philpott PJ, Shapiro H. Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer J Urol 1996, 156: 110-3
13. Theiss M, Wirth MP, Manseck A, Frohmüller HGW. Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate 1995; 27: 13-7.
14. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993; 16: 499-509.
15. Stein A, deKernion JB, Smith RB, Dorey F, Patel H Prostate tate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992; 147: 942-6.
16. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prustatectomy. Urol Clin North Am 1993; 20: 713-25.
17. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-7.
18. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 1821-5.
19. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickhott JT, Zincke H. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996; 156: 137-43.
20. Gibbons RP, Correa RJ Jr, Brannen GE, Weissman RM. Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol 1989; 141. 564-6.
21. Paulsson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical T1-2N0M0 prostatic adenocarcinoma: long-term results J Urol 1990; 144: 1180-4.
22. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-42.
23. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-9.
24. Davidson PJT, van der Ouden D, Schroeder FH. Radical prostatectomy: prospective assessment of mortality and morbidity. Eur Urol 1996; 29: 168-73.
25. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assess ment of radical prostatectomy. JAMA 1993, 269: 2633-6.
26. Häggman M, Brandstedt S, Norlén BJ. Rectal perforation after retropubic radical prostatectomy: occurrence and management. Eur Urol 1996; 29: 337-40
27. Andriole GL, Smith DS, Rao G, Goodnough L, Catalona WJ. Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol 1994; 152: 1858-60.
28. Fowler JE Jr, Barry MJ, Lu-Yao GL, Roman A, Wasson J, Wennberg JE Patient-reported complications and follow-up treatment after radical prostatectomy. Urology 1993; 42: 623-9
29. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual func tion following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991; 145: 998-1002.
30. Jønler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of radical prostatectomy. Br J Urol 1994; 74: 352-8.
31. Flemming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993; 269: 2650-8.
32. Beck JR, Kattan MW, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol 1994; 152: 1894-9.
33. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R. Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol 1991; 9: 328-34.
34. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-35.
35. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Arch Fam Med 1993; 2: 487-93.
36. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8.
37. Brasso K, Friis S, Juel K, Jørgensen T, Iversen P. Lokaliseret cancer prostatale. Overlevelse og tab af leveår. Ugeskr Læger 1998; 160: 4517-20.
38. Hugosson J, Aus G, Bergdahl C, Bergdahl S. Prostate cancer mortality in patients surviving more than 10 years after diagnosis J Urol 1995, 154: 2115-7
39. Dillioglugil Ö, Miles BJ, Scardino PT. Current controversies in the management of localized prostate cancer. Eur Urol 1995; 28: 85-101.
40. Brasso K, Friis S, Kjær SK, Iversen P. Cancer prostatae hos mænd under 65 är, forekomst og behov for udredning. Ugeskr Læger 1997; 159: 2543-5.